Guided Therapeutics Inc. (OTCMKTS:GTHP) Short Interest Down 28.4% in December

Guided Therapeutics Inc. (OTCMKTS:GTHP) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 1,846 shares, a decline of 28.4% from the November 30th total of 2,580 shares. Based on an average daily volume of 13,148 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the company’s stock are sold short. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 13,148 shares, the days-to-cover ratio is presently 0.1 days.

Guided Therapeutics Price Performance

GTHP traded up $0.13 during trading on Wednesday, reaching $0.53. The company had a trading volume of 125,382 shares, compared to its average volume of 14,282. The company has a market cap of $45.83 million, a P/E ratio of -10.66 and a beta of 0.64. The business’s fifty day moving average price is $0.26 and its 200 day moving average price is $0.26. Guided Therapeutics has a 12 month low of $0.06 and a 12 month high of $0.54.

Guided Therapeutics (OTCMKTS:GTHP) last released its earnings results on Thursday, November 13th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.06 million during the quarter.

About Guided Therapeutics

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.